Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.37 |
| ▸ | LPL | P06858 | 4/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | P4HB | P07237 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15912438 | 0.84 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1POLBLIPG | |
| SCHEMBL9940441 | 0.82 | ALDH1A1 (0.45) | ALDH1A1POLBLIPGLPLCA1 | |
| SCHEMBL14709239 | 0.81 | ALDH1A1 (0.46) | ALDH1A1POLBCYP2C19LMNATSHR | |
| SCHEMBL15897466 | 0.78 | ALDH1A1 (0.44) | ALDH1A1LIPGLPLCYP2C19LMNA | |
| SCHEMBL12989610 | 0.75 | CA1 (0.47) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL14709101 | 0.75 | CA1 (0.42) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL31158444 | 0.73 | LPL (0.42) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL15774984 | 0.73 | LPL (0.45) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL14790503 | 0.73 | LIPG (0.45) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL3680238 | 0.73 | F11 (0.48) | LIPGLPLCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-31 | — | — | US | disclosed |
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | MEN1 1384/4885KMT2A 2450/4885ALDH1A1 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.